Enhanced Medical Nutrition Secures $5M Series A Funding for Surgical Nutrition Innovation
Enhanced Medical Nutrition, Inc. (EMN), a pioneering food-as-medicine company, has secured a significant USD $5 million over-subscribed Series A financing round. This funding is led by dsm-firmenich Venturing and the Corporate Venture Capital (CVC) arm of Ajinomoto Co., Inc., with participation from PeakBridge, Elder Ventures, angel investors, and existing shareholders.
The funds will be utilized to scale the expansion of ENROUTE, an innovative nutrition program designed specifically for the dietary management of surgery. EMN aims to revolutionize surgical care by leveraging nutrition technology to reduce risk, accelerate recovery, and enhance overall patient outcomes.
EMN’s mission is to improve outcomes in surgery with nutrition, addressing a critical gap in solutions tailored to patients’ needs. The company develops medical nutrition products to help patients prepare better and recover faster from surgery. Their flagship product, ENROUTE, is a proprietary, evidence-based nutrition program that addresses the unique nutritional requirements of patients undergoing surgery.
ENROUTE is designed to reduce risk, accelerate recovery, and enhance overall patient outcomes by providing targeted nutrients and addressing deficiencies to support the body’s healing processes, including muscle mass, tissue repair, and immune function. Administered pre- and post-operatively, ENROUTE seamlessly integrates into surgical protocols, enabling healthcare providers to incorporate medical nutrition for their patients.
The investment in EMN reflects a strategic partnership with dsm-firmenich Venturing and Ajinomoto, both of which have a strong interest in the impact of nutritional supplementation for surgical patients. This partnership aligns with their vision of leveraging functional ingredients and empowering market-ready solutions that improve human health.
PeakBridge’s participation in the funding round underscores their commitment to supporting innovative solutions in the food-as-medicine space. EMN’s approach brings an essential and timely innovation to an underserved market, one that will significantly improve patient outcomes and drive meaningful progress in healthcare nutrition.
The funding will enable EMN to accelerate its mission and vision of supporting surgeons and their care teams and positively influencing patients. The company plans to expand ENROUTE across North America, addressing the significant gap in solutions tailored to patients’ nutritional needs during surgery.
EMN’s dedication to scientific validation and patient-centric innovation positions the company to significantly impact the standard of care in surgery. This financing marks an exciting step for the company as it expands its reach and delivers value to a growing market.
The investment in EMN is a continuation of Ajinomoto’s investment in medical nutrition, focusing on the impact of nutritional supplementation for surgical patients from prehabilitation to rehabilitation to healthy aging. This strategic partnership will help EMN scale its impact as it transforms surgical care and improves patient outcomes.
Overall, the funding secured by EMN is a significant milestone in the company’s journey to revolutionize nutrition for surgery. With the support of its investors, EMN is poised to make a significant impact in the healthcare industry by leveraging nutrition technology to improve patient outcomes.
See more funded startups in USA.